Category: Tool-products

LIVE Q&A KOL EVENTTG4050: Individualized cancer Vaccinein HPV-Negative Head & Neck Cancers April 19, 2023 | 12:00 PM ET CLICK TO REGISTER & ATTEND

TG6050 TG6050, an innovative oncolytic virus from the Invir.IO® platform, armed oncolytic virus given by intravenous administration. TG6050 has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.    Discover how TG6050 works A novel immunotherapy TG6050 is based on a patented viral… Continue reading produits : TG6050 – en

TG4001  Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers Read the press release – Download the presentation Watch our analyst call discussing the results

Find Out How Transgene’s Virus Powered ImmunotherapiesCan Transform the Treatment of Solid Tumors R&D Day – ParisSeptember 27, 2022 Detailed Program – Watch the webcast – Presentation

TG4050 TG4050 is an individualized therapeutic vaccine A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.   –> article annonce 28362 ou substitut 28368 Collaboration agreements Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each… Continue reading TG4050

First clinical benefits in head and neck cancer – Proof of principle data — All treated patients remain disease-free after a median follow up of 18.6 months   Press release [PDF] Poster presented at AACR 2024 Listen to Dr. Alessandro Riva’s comments, Chairman & CEO of Transgene  (VOST) Liste to the KOL Event TG4050 (April,… Continue reading annonce TG4050en

TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)

A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video

One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce

BT-001 BT-001 is a multifunctional oncolytic virus encoding for an anti-CTLA4 antibody and GM-CSF BT-001 is the first oncolytic virus from Invir.IO® and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which… Continue reading produits : BT-001